Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation.
Baicalin is one of the main bioactive flavone glucuronides derived as a medicinal herb from the dried roots of Scutellaria baicalensis Georgi, and it is widely used for the treatment of fever, inflammation, and other conditions. Due to baicalin's poor solubility in water, its absolute bioavailability after oral administration is only 2.2%. The objective of this study was to develop a novel baicalin-loaded nanoemulsion to improve the oral bioavailability of baicalin. Based on the result of pseudoternary phase diagram, the nanoemulsion formulation consisting of soy-lecithin, tween-80, polyethylene glycol 400, isopropyl myristate, and water (1:2:1.5:3.75:8.25, w/w) was selected for further study. Baicalin-loaded nanoemulsions (BAN-1 and BAN-2) were prepared by internal or external drug addition and in vivo and in vitro evaluations were performed. The results showed that the mean droplet size, polydispersity index, and drug content of BAN-1 and BAN-2 were 91.2 ± 2.36 nm and 89.7 ± 3.05 nm, 0.313 ± 0.002 and 0.265 ± 0.001, and 98.56% ± 0.79% and 99.40% ± 0.51%, respectively. Transmission electron microscopy revealed spherical globules and confirmed droplet size analysis. After dilution 30-fold with water, the solubilization capacity of BAN-1 and BAN-2 did not change. In vitro release results showed sustained-release characteristics. BAN-1 formulation was stable for at least 6 months and was more stable than BAN-2. In rats, the area under the plasma drug concentration-time curve value of BAN-1 was 1.8-fold and 7-fold greater than those of BAN-2 and free baicalin suspension after oral administration at a dose of 100 mg/kg. In conclusion, these results demonstrated that the baicalin-loaded nanoemulsion formulation, in particular BAN-1, was very effective for improving the oral bioavailability of baicalin and exhibited great potential for future clinical application.
['Zhao|Ling|L|', 'Wei|Yumeng|Y|', 'Huang|Yu|Y|', 'He|Bing|B|', 'Zhou|Yang|Y|', 'Fu|Junjiang|J|']
D000284:Administration, Oral D000818:Animals D000894:Anti-Inflammatory Agents, Non-Steroidal D001682:Biological Availability D003692:Delayed-Action Preparations D004339:Drug Compounding D004655:Emulsions D005419:Flavonoids D066298:In Vitro Techniques D008297:Male D008657:Metabolic Clearance Rate D009055:Mouth D053769:Nanocapsules D010316:Particle Size D051381:Rats D017207:Rats, Sprague-Dawley
nanoemulsion oral bioavailability baicalin pharmacokinetics